Literature DB >> 21525967

Management of blood pressure in patients with diabetes.

Ehud Grossman1, Franz H Messerli.   

Abstract

Hypertension is a major modifiable risk factor for cardiovascular morbidity and mortality in patients with diabetes. Lowering blood pressure (BP) to 135/85 mm Hg is the main goal of treatment. A nonpharmcologic approach is recommended in all patients. If BP levels remain above the target despite nonpharmacologic treatment, drug therapy should be initiated. Blockers of the renin-angiotensin-aldosterone system (RAAS) represent the cornerstone of the antihypertensive drug arsenal; however, in most patients, combination therapy is required. For many patients, a combination of RAAS blocker and calcium antagonist is the combination preferred by the treating physician. Often three or even four drugs are needed. Treatment should be individualized according to concomitant risk factors and diseases and depending on the age and hemodynamic and laboratory parameters of the patient. In order to maximally reduce cardio renal risk, control of lipid and glycemic levels should also be ensured.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525967     DOI: 10.1038/ajh.2011.77

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  11 in total

Review 1.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

2.  Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.

Authors:  Emily B Schroeder; Michel Chonchol; Susan M Shetterly; J David Powers; John L Adams; Julie A Schmittdiel; Gregory A Nichols; Patrick J O'Connor; John F Steiner
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-23       Impact factor: 8.237

3.  Economic cost of primary prevention of cardiovascular diseases in Tanzania.

Authors:  Frida Ngalesoni; George Ruhago; Ole F Norheim; Bjarne Robberstad
Journal:  Health Policy Plan       Date:  2014-08-11       Impact factor: 3.344

Review 4.  Obesity and diabetic kidney disease.

Authors:  Christine Maric-Bilkan
Journal:  Med Clin North Am       Date:  2012-11-27       Impact factor: 5.456

Review 5.  Obesity in kidney disease: A heavyweight opponent.

Authors:  Raphael Jose Ferreira Felizardo; Marina Burgos da Silva; Cristhiane Favero Aguiar; Niels Olsen Saraiva Câmara
Journal:  World J Nephrol       Date:  2014-08-06

Review 6.  Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011?

Authors:  Peter M Nilsson
Journal:  J Zhejiang Univ Sci B       Date:  2011-08       Impact factor: 3.066

7.  The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient.

Authors:  Graziano Riccioni
Journal:  Ther Adv Endocrinol Metab       Date:  2013-10       Impact factor: 3.565

8.  Out-of-office blood pressure: from measurement to control.

Authors:  Jean-Philippe Baguet
Journal:  Integr Blood Press Control       Date:  2012-05-16

9.  Clinical Significance of Arterial Stiffness and Thickness Biomarkers in Type 2 Diabetes Mellitus: An Up-To-Date Meta-Analysis.

Authors:  Yang Yapei; Ren Xiaoyan; Zeng Sha; Pan Li; Meng Xiao; Chen Shuangfeng; Wang Lexin; Cui Lianqun
Journal:  Med Sci Monit       Date:  2015-08-21

10.  Higher prevalence and awareness, but lower control rate of hypertension in patients with diabetes than general population: the fifth korean national health and nutrition examination survey in 2011.

Authors:  Seung-Hyun Ko; Hyuk-Sang Kwon; Dae Jung Kim; Jae Hyeon Kim; Nan Hee Kim; Chul Sik Kim; Kee-Ho Song; Jong Chul Won; Soo Lim; Sung Hee Choi; Kyungdo Han; Yong-Moon Park; Bong-Yun Cha
Journal:  Diabetes Metab J       Date:  2014-02-19       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.